59.43 USD
+0.44 (+0.75%)
59.43 USD
0 (0%)
Overall BMRN gets a fundamental rating of 6 out of 10. We evaluated BMRN against 530 industry peers in the Biotechnology industry. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on BMRN. These ratings could make BMRN a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
In the past year BMRN was profitable.
In the past year BMRN had a positive cash flow from operations.
BMRN had positive earnings in 4 of the past 5 years.
In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
BMRN's Return On Assets of 6.83% is amongst the best of the industry. BMRN outperforms 92.64% of its industry peers.
Looking at the Return On Equity, with a value of 8.59%, BMRN belongs to the top of the industry, outperforming 92.08% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 7.69%, BMRN belongs to the top of the industry, outperforming 93.96% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BMRN is significantly below the industry average of 18.28%.
The last Return On Invested Capital (7.69%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 16.82%, BMRN belongs to the best of the industry, outperforming 92.64% of the companies in the same industry.
BMRN's Operating Margin of 20.21% is amongst the best of the industry. BMRN outperforms 94.53% of its industry peers.
With an excellent Gross Margin value of 81.32%, BMRN belongs to the best of the industry, outperforming 85.28% of the companies in the same industry.
BMRN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMRN is destroying value.
The number of shares outstanding for BMRN has been increased compared to 1 year ago.
BMRN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BMRN has an improved debt to assets ratio.
2.2 Solvency
BMRN has an Altman-Z score of 5.59. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
BMRN has a better Altman-Z score (5.59) than 73.77% of its industry peers.
BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.72, BMRN belongs to the top of the industry, outperforming 94.53% of the companies in the same industry.
BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
BMRN's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 62.08% of its industry peers.
Although BMRN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.59 |
ROIC/WACC0.92
WACC8.35%
2.3 Liquidity
A Current Ratio of 4.83 indicates that BMRN has no problem at all paying its short term obligations.
With a Current ratio value of 4.83, BMRN perfoms like the industry average, outperforming 56.04% of the companies in the same industry.
A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
With a Quick ratio value of 3.10, BMRN is not doing good in the industry: 60.75% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.00%, which is quite impressive.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.39%.
The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 27.59% on average per year.
BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.34% yearly.
EPS Next Y35.7%
EPS Next 2Y42.79%
EPS Next 3Y35.49%
EPS Next 5Y27.59%
Revenue Next Year12.48%
Revenue Next 2Y10.76%
Revenue Next 3Y10.23%
Revenue Next 5Y7.34%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 22.34, which indicates a rather expensive current valuation of BMRN.
BMRN's Price/Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 94.34% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. BMRN is around the same levels.
BMRN is valuated correctly with a Price/Forward Earnings ratio of 13.19.
Based on the Price/Forward Earnings ratio, BMRN is valued cheaply inside the industry as 96.79% of the companies are valued more expensively.
BMRN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.34 | ||
| Fwd PE | 13.19 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 95.09% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, BMRN is valued cheaply inside the industry as 97.17% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.83 | ||
| EV/EBITDA | 14.56 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 35.49% in the coming years.
PEG (NY)0.63
PEG (5Y)N/A
EPS Next 2Y42.79%
EPS Next 3Y35.49%
5. Dividend
5.1 Amount
No dividends for BMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
59.43
+0.44 (+0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.86%
Inst Owner Change-1%
Ins Owners0.65%
Ins Owner Change-0.62%
Market Cap11.42B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts82.35
Price Target92.08 (54.94%)
Short Float %4.25%
Short Ratio2.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-2.16%
PT rev (3m)-6.22%
EPS NQ rev (1m)-3.95%
EPS NQ rev (3m)8.57%
EPS NY rev (1m)-1.25%
EPS NY rev (3m)-14.9%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)0.79%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.34 | ||
| Fwd PE | 13.19 | ||
| P/S | 3.69 | ||
| P/FCF | 13.83 | ||
| P/OCF | 12.49 | ||
| P/B | 1.89 | ||
| P/tB | 2.03 | ||
| EV/EBITDA | 14.56 |
EPS(TTM)2.66
EY4.48%
EPS(NY)4.51
Fwd EY7.58%
FCF(TTM)4.3
FCFY7.23%
OCF(TTM)4.76
OCFY8.01%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.63
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.59 |
F-Score8
WACC8.35%
ROIC/WACC0.92
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y35.7%
EPS Next 2Y42.79%
EPS Next 3Y35.49%
EPS Next 5Y27.59%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.48%
Revenue Next 2Y10.76%
Revenue Next 3Y10.23%
Revenue Next 5Y7.34%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.07%
EBIT Next 3Y41.21%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
What is the valuation status for BMRN stock?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 35.7% in the next year.